Literature DB >> 14606017

Clinical evaluation of combined endoscopic variceal ligation and sclerotherapy of gastric varices in liver cirrhosis.

Y Arakaki1, K Murakami, K Takahashi, R Sato, T Okimoto, H Ishitobi, M Nasu, J Kagawa, M Kodama, T Fujioka.   

Abstract

BACKGROUND AND STUDY AIMS: Endoscopic injection sclerotherapy (EIS) using cyanoacrylate and balloon-occluded retrograde transvenous obliteration (B-RTO) are the main procedures used to treat gastric varices. However, neither technique is free of problems. EIS for gastric varices may cause embolism in other organs; B-RTO requires a gastrorenal shunt and may aggravate esophageal varices. We have developed a combined form of endoscopic therapy involving band ligation and sclerotherapy which is an effective and safe procedure for treating gastric varices. PATIENTS AND METHODS: Fifty-six patients with gastric varices and liver cirrhosis were treated at Almeida Memorial Hospital from June 1997 to May 2002 using the combined procedure. Each gastric varix was tightly ligated with O-rings, and 1 % polidocanol was injected into the submucosa around the ligated varix. If necessary, additional sclerotherapy was carried out after the initial treatment.
RESULTS: The rate of hemostasis for variceal bleeding was 100 %, and no critical complications were noted. Complete disappearance of the gastric varices was observed endoscopically in all cases. Computed tomography showed that collateral vessels outside the gastric wall were not occluded by the treatment. Endoscopic follow-up examinations were carried out, and gastric varices recurred in seven patients (12.5 %). Only two of the patients (3.6 %) had a small amount of oozing bleeding. Additional endoscopic variceal ligation (EVL) and/or EIS were performed in these seven cases, and none of the patients died as a result of a bleeding gastric varix.
CONCLUSIONS: The combined procedure was easily performed immediately after endoscopic examination, and required no special apparatus. It was found to be a safe and effective method of treating gastric varices.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14606017     DOI: 10.1055/s-2003-43475

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  6 in total

1.  A modified percutaneous transhepatic variceal embolization with 2-octyl cyanoacrylate versus endoscopic ligation in esophageal variceal bleeding management: randomized controlled trial.

Authors:  Chun Qing Zhang; Fu Li Liu; Bo Liang; Zi Qin Sun; Hong Wei Xu; Lin Xu; Kai Feng; Zun Chang Liu
Journal:  Dig Dis Sci       Date:  2007-11-21       Impact factor: 3.199

Review 2.  Endoscopic management of bleeding gastric varices--an updated overview.

Authors:  Dana Crisan; Marcel Tantau; Alina Tantau
Journal:  Curr Gastroenterol Rep       Date:  2014-10

3.  Foam sclerotherapy using polidocanol for balloon-occluded retrograde transvenous obliteration (BRTO).

Authors:  Sun Young Choi; Jong Yun Won; Kyung Ah Kim; Do Yun Lee; Kwang-Hun Lee
Journal:  Eur Radiol       Date:  2010-08-26       Impact factor: 5.315

Review 4.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part 1.

Authors:  Sharad Sharma; Ahmet Gurakar; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2007-11-09       Impact factor: 3.199

5.  Endoscopic hemostasis for bleeding gastric varices treated by combination of variceal ligation and sclerotherapy with N-butyl-2-cyanoacrylate.

Authors:  Nozomi Sugimoto; Kenichiro Watanabe; Kazuyo Watanabe; Shinichi Ogata; Ryo Shimoda; Hiroyuki Sakata; Yuichiro Eguchi; Toshihiko Mizuta; Seiji Tsunada; Ryuichi Iwakiri; Junichi Nojiri; Masanobu Mizuguchi; Sho Kudo; Kohji Miyazaki; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

6.  Safety and Efficacy of a Novel Shunt Surgery Combined with Foam Sclerotherapy of Varices for Prehepatic Portal Hypertension: A Pilot Study.

Authors:  Zhe Zhang; Xueming Chen; Chenyu Li; Hai Feng; Hongzhi Yu; Renming Zhu; Tianyou Wang
Journal:  Clinics (Sao Paulo)       Date:  2019-08-19       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.